Hongbo Lu
CIK 1767584 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TERN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | 426,736 | $28.26 | $12.06M | $7.65M | 7 | 2026-06-17 |
| ARWR | Director | 52,012 | $58.16 | $3.03M | -$145.3K | 4 | 2026-05-14 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 476,190 | $52.95 | $25.21M | $19.64M | 11 | 2025-06-12 |
| AVEDRO INC (AVDR) Delisted | Director | — | $24.25 | — | $0 | 3 | 2019-11-25 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 1,727,550 | $76.01 | $131.31M | $1.08M | 1 | 2019-04-24 |
Recent Filings · Page 2 of 3
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-03 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-20 | ARWR | Grant (A) | +16,733 | $384.7K | EDGAR |
| 2024-09-17 | ZBIO | Buy (P) | +58,823 | $1000.0K | EDGAR |
| 2024-09-17 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +476,190 | $5.00M | EDGAR |
| 2024-09-16 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-20 | ARWR | Buy (P) | +3,000 | $83.0K | EDGAR |
| 2023-06-14 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-23 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +758,620 | $5.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.